Fauci says 'prudent' to have Omicron vaccine, but may not be needed
Reuters
Published Jan 25, 2022 11:06AM ET
Updated Jan 25, 2022 11:25AM ET
WASHINGTON (Reuters) -A COVID-19 vaccine specifically targeting the Omicron variant would be "prudent" even if it ultimately may not be needed, the top U.S. infectious disease official said on Tuesday as Pfizer announced trials for such a vaccine.
"It makes sense to think in terms of at least having ready an Omicron specific boost," Dr. Anthony Fauci, President Joe Biden's top medical adviser and a member of the White House COVID-19 Response Team, told MSNBC.
"We may not need it... but I think it's prudent to at least prepare for the possibility that this may be a persistent variant that we may have to face - even if it's at a very low level," he added.
Earlier on Tuesday, Pfizer Inc (NYSE:PFE) and its partner BioNTech SE (NASDAQ:BNTX) said they have started clinical trials for a version of their vaccine targeting the highly-transmissible variant that has eluded their current two-dose protection and led to breakthrough infections.
While much of the nation is still grappling with high Omicron infections even as cases subside in some states, Fauci said eventually enough community immunity will hopefully build up to prevent massive surges such as the four to five waves driven by variants so far.
"I don't think we're going to be seeing that indefinitely," he said, adding that COVID was unlikely to be eradicated.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.